El Lilly Acquires Centessa for $7.8 B to Boost Neuroscience & Orexin TherapyDiscover how Eli Lilly’s $7.8 B acquisition of Centessa adds orexin‑targeted narcolepsy drugs, boosting its neuroscience portfolio and market impact.CENTESSA PHARMACEUTICALS Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 24/06/2026, 14:53 2 minutes to read